\n\u00a0\n<\/p>\n<\/td>\n
Year ended<\/b><\/p>\n<\/td>\n<\/tr>\n (in millions, US$)<\/i><\/p>\n<\/td>\n December 31, \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \nLoss for the year\n<\/p>\n<\/td>\n \n(292.2)~(324.9)\n<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \nShare based payment expenses, net\n<\/p>\n<\/td>\n \n4.5~5.2\n<\/p>\n<\/td>\n<\/tr>\n \nExchange differences, net\n<\/p>\n<\/td>\n \n(0.1)\n<\/p>\n<\/td>\n<\/tr>\n \nListing Expenses\n<\/p>\n<\/td>\n \n1.4\n<\/p>\n<\/td>\n<\/tr>\n \nService fee for the issuance of Series A Preference Shares\n<\/p>\n<\/td>\n \n4.0\n<\/p>\n<\/td>\n<\/tr>\n \nFair value loss of convertible redeemable Series A Preference Shares\n<\/p>\n<\/td>\n \n80.0\n<\/p>\n<\/td>\n<\/tr>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \nAdjusted loss for the year\n<\/p>\n<\/td>\n \n(202.4)~(234.4)\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \nAdjusted loss for the year is a non-IFRS financial measure. Legend Biotech is reporting Adjusted loss for the year because this financial measure is to be reported as part of a Profit Warning announcement issued by Legend Biotech\u2019s majority parent company, GenScript Biotech Corporation, pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. Adjusted loss for the year has limitations in that it does not reflect all expense items that affect Legend Biotech\u2019s results.\n<\/p>\n \nNon-IFRS measures are not meant to be considered in isolation or as a substitute for financial information presented in accordance with IFRS and should be viewed as supplemental and in addition to Legend Biotech\u2019s financial information presented in accordance with IFRS.\n<\/p>\n About Ciltacabtagene autoleucel (cilta-cel)<\/b><\/p>\n Cilta-cel is an investigational chimeric antigen receptor T cell (CAR-T) therapy, formerly identified as JNJ-4528 outside of China and LCAR-B38M CAR-T cells in China, that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed and\/or refractory multiple myeloma and in earlier lines of treatment. The design consists of a structurally differentiated CAR-T with two BCMA-targeting single domain antibodies. In December 2017, Legend Biotech, Inc. entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc. to develop and commercialize cilta-cel. <\/span><\/p>\n\n In addition to a Breakthrough Therapy Designation (BTD) granted in the U.S. in December 2019, cilta-cel received a BTD in China in August 2020. In addition, Orphan Drug Designation was granted for cilta-cel by the U.S. FDA in February 2019, and by the European Commission in February 2020. <\/span><\/p>\n About Legend Biotech<\/b><\/p>\n \nLegend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our team of over 800 employees across the United States, China and Europe, along with our differentiated technology, global development, and manufacturing strategies and expertise, provide us with the strong potential to discover, develop, and manufacture cutting edge cell therapies for patients in need.\n<\/p>\n \nWe are engaged in a strategic collaboration to develop and commercialize our lead product candidate, ciltacabtagene autoleucel, an investigational BCMA-targeted CAR-T cell therapy for patients living with multiple myeloma. This candidate is currently being studied in registrational clinical trials.\n<\/p>\n \nTo learn more about Legend Biotech, visit us on LinkedIn<\/a>, or on Twitter @LegendBiotech<\/a> or at www.legendbiotech.com<\/a>.\n<\/p>\n Cautionary Note Regarding Forward-Looking Statements<\/b><\/p>\n \nStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, constitute \u201cforward-looking statements\u201d within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to anticipated financial results for the year ended December 31, 2020, including expected research and development expenses. The words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including as a result of items or events identified during the completion of management\u2019s and Legend Biotech\u2019s audit committee\u2019s reviews and other financial closing processes, potential audit adjustments related to the completion of the audit by Legend Biotech\u2019s independent auditor, and the factors discussed in the \u201cRisk Factors\u201d section of the prospectus filed with the Securities and Exchange Commission on June 8, 2020. Any forward-looking statements contained in this press release speak only as of the date hereof, and Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.\n<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210219005038\/en\/<\/a><\/span><\/p>\n \nMedia and Investor Relations:\n<\/p>\n \nJessie Yeung, Head of Corporate Finance and Investor Relations, Legend Biotech \nSurabhi Verma, Manager of Investor Relations and Corporate Communications, Legend Biotech KEYWORDS:<\/b> United States North America New Jersey<\/p>\n INDUSTRY KEYWORDS:<\/b> Biotechnology Health Pharmaceutical Clinical Trials Oncology<\/p>\n MEDIA:<\/b><\/p>\n Legend Biotech Announces Preliminary Results for the Year Ended December 31, 2020 SOMERSET, N.J.–(BUSINESS WIRE)– Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today in conjunction with an announcement to be issued by Legend Biotech\u2019s majority parent company, GenScript Biotech Corporation, pursuant to the rules of The Stock Exchange of Hong Kong Limited, announced preliminary, unaudited financial results for the year ended December 31, 2020. For the year ended December 31, 2020, Legend Biotech expects to record a loss for the year of approximately US$292.2 million to US$324.9 million and an adjusted loss for the year of approximately US$202.4 million to … <\/p>\n\n \n \n \n \n
\n
2020<\/b><\/p>\n<\/td>\n<\/tr>\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n <\/p>\n
\n
jessie.yeung@legendbiotech.com <\/a>or
\n
investor@legendbiotech.com<\/a><\/p>\n
\n
Surabhi.Verma@legendbiotech.com<\/a> or
\n
media@legendbiotech.com<\/a><\/p>\n\n","protected":false},"excerpt":{"rendered":"